1. Generics Bulletin

Stada’s Rare Kidney Disease Drug Is EU First

Germany First In Line For The Orphan Disease Drug

 
• By Rosalind Rei

Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.

EU flag, with its stars encircling a picture of a drug capsule
Stada's Kinpeygo (Budesonide) is currently the only EU-approved drug treatment for IgAN • Source: Shutterstock

Stada has launched the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy (IgAN), also known as Berger’s disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business